ACAP3

Across TCGA pan-cancer cohorts, ACAP3 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ACAP3 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ACAP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACAP3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, KICH, and KIRP are the cancer types where ACAP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.128	0.783	.001	30	view →
KICH	OS	Median	All	0.161	0.881	<.001	24	view →
KIRP	DFS	Median	II,III,IV	0.037	0.783	<.001	13	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
LUAD	DFS	Median	III,IV	0.036	0.673	<.001	6	view →
BLCA	DFS	Median	All	0.784	0.325	.041	5	view →
BRCA	OS	Median	All	0.181	0.579	.028	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ACAP3–LIHC (OS)

Open the LIHC breakdown →